|
|
 |
Workshop on the Development of Broad Spectrum TherapeuticsOffice of Biodefense Research Affairs (OBRA)
Office of Regulatory Affairs (ORA)
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
April 18, 2006
Workshop Summary (PDF)
| Presentations |
| Development of Novel Broad Spectrum Antibiotics Using A Novel Target |
Dr. M.R.K. (Dickon) Alley, PhD
Head of Discovery Biology, Anacor Pharmaceuticals, Inc. |
| Development of Broad Spectrum Antibiotics |
Dr. Mark Goldberger MD, MPH
Director, Office of Antimicrobial Products
FDA, CDER |
| Non-Clinical Microbiology Studies to Support Development of Broad Spectrum Therapeutics |
Dr. Fred Marsik, PhD
Microbiologist
FDA, CDER |
| Making Novel Antibacterials: New Targets or New Structures? |
Dr. David Pompliano, PhD
Vice President, Biology
GlaxoSmithKline |
Regulatory Path for Nonclinical Studies to Support Development of Broad Spectrum Therapeutics
Pharmacology/Toxicology |
CDR William H. Taylor, PhD, DABT
Pharmacology/Toxicology Team Leader
FDA, CDER | |
|
|
|